Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:
   

Tamasek Invests $250 Million in Columbia Pacific for China Hospitals

publication date: Oct 20, 2016
Columbia Pacific Management, an Asia healthcare provider based in Seattle, formed a 50/50 JV with Temasek to build healthcare facilities in China. Temasek is the sovereign wealth fund of Singapore. The JV, Columbia China, is the China division of Columbia Pacific. Columbia China already owns hospitals, clinics and senior living facilities in China, and it has more under construction. Temasek will invest $250 million into the JV for its 50% stake. With the money, Columbia China will add to its development projects. More details....

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes


Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital